Trifluoromethyl Oxetanes: Synthesis and Evaluation as a tert‐Butyl Isostere
暂无分享,去创建一个
[1] K. F. Morgan,et al. Oxetanes: Recent Advances in Synthesis, Reactivity, and Medicinal Chemistry. , 2016, Chemical reviews.
[2] Gregory W. Kauffman,et al. Design of Pyridopyrazine-1,6-dione γ-Secretase Modulators that Align Potency, MDR Efflux Ratio, and Metabolic Stability. , 2015, ACS medicinal chemistry letters.
[3] E. Carreira,et al. Evaluation of tert‐Butyl Isosteres: Case Studies of Physicochemical and Pharmacokinetic Properties, Efficacies, and Activities , 2015, ChemMedChem.
[4] Gregory W. Kauffman,et al. Design, synthesis, and pharmacological evaluation of a novel series of pyridopyrazine-1,6-dione γ-secretase modulators. , 2014, Journal of medicinal chemistry.
[5] Monish Jain,et al. Metabolically Stable tert-Butyl Replacement. , 2013, ACS medicinal chemistry letters.
[6] G. Kay,et al. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. , 2011, British journal of clinical pharmacology.
[7] Erick M. Carreira,et al. Oxetane als vielseitige Bausteine in der Wirkstoff‐Forschung und Synthese , 2010 .
[8] E. Carreira,et al. Oxetanes as versatile elements in drug discovery and synthesis. , 2010, Angewandte Chemie.
[9] A. A. Fokin,et al. Stereospecific consecutive epoxide ring expansion with dimethylsulfoxonium methylide. , 2010, The Journal of organic chemistry.
[10] C. Molinaro,et al. Resolution of 2,2-disubstituted epoxides via biocatalytic azidolysis. , 2010, Organic letters.
[11] Franz Schuler,et al. Oxetanes in drug discovery: structural and synthetic insights. , 2010, Journal of medicinal chemistry.
[12] P. Verhoest,et al. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. , 2010, ACS chemical neuroscience.
[13] C. Humblet,et al. Escape from flatland: increasing saturation as an approach to improving clinical success. , 2009, Journal of medicinal chemistry.
[14] Dafydd R Owen,et al. Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis. , 2009, Bioorganic & medicinal chemistry letters.
[15] S. Matsunaga,et al. Catalytic asymmetric synthesis of 2,2-disubstituted oxetanes from ketones by using a one-pot sequential addition of sulfur ylide. , 2009, Angewandte Chemie.
[16] Bo Feng,et al. In Vitro P-glycoprotein Assays to Predict the in Vivo Interactions of P-glycoprotein with Drugs in the Central Nervous System , 2008, Drug Metabolism and Disposition.
[17] Y. Shishido,et al. Synthesis of aromatic compounds containing a 1,1-dialkyl-2-trifluoromethyl group, a bioisostere of the tert-alkyl moiety. , 2007, Bioorganic & medicinal chemistry letters.
[18] E. Carreira,et al. Oxetanes as promising modules in drug discovery. , 2006, Angewandte Chemie.
[19] R. Austin,et al. A UNIFIED MODEL FOR PREDICTING HUMAN HEPATIC, METABOLIC CLEARANCE FROM IN VITRO INTRINSIC CLEARANCE DATA IN HEPATOCYTES AND MICROSOMES , 2005, Drug Metabolism and Disposition.
[20] K. Okuma,et al. Reaction of dimethyloxosulfonium methylide with epoxides. Preparation of oxetanes , 1983 .
[21] D. Dess,et al. Readily accessible 12-I-5 oxidant for the conversion of primary and secondary alcohols to aldehydes and ketones , 1983 .
[22] B. Landrum,et al. Synthesis of partially fluorinated oxetanes , 1965 .
[23] E. Corey,et al. Dimethyloxosulfonium Methylide ((CH3)2SOCH2) and Dimethylsulfonium Methylide ((CH3)2SCH2). Formation and Application to Organic Synthesis , 1965 .
[24] Martin Pettersson,et al. γ-Secretase Modulators as Aβ42-Lowering Pharmacological Agents to Treat Alzheimer’s Disease , 2017 .
[25] Ramesh Krishnamurti,et al. Synthetic methods and reactions. 141. Fluoride-induced trifluoromethylation of carbonyl compounds with trifluoromethyltrimethylsilane (TMS-CF3). A trifluoromethide equivalent , 1989 .
[26] I. Ruppert,et al. Die ersten CF3-substituierten organyl(chlor)silane , 1984 .